SRS16-86

Research use only, not for human use.

SRS16-86 is a novel third-generation ferrostatin, is an inhibitor of ferroptosis.

SRS16-86 is a novel third-generation ferrostatin, is an inhibitor of ferroptosis.

——

Animal Model:Renal IRI model Dosage:2 mg/kg; 15 min before the onset of surgery Administration:Intraperitoneal injection; 2 mg/kg; 15 min before the onset of surgery Result:Was protective from renal IRI. Animal Model:Renal IRI modelDosage:2 mg/kg Administration:Combination with Necrostatin-1/ Sanglifehrin A; 2 mg/kg; 4 weeks Result:Further increased the protective effect of [Necrostatin-1/Sanglifehrin A] combination therapy in renal IRI model.

——

Apoptosis

Ferroptosis

ferroptosis

——

——

1793052-96-6

432.6

C26H32N4O2

>98% (HPLC)

DMSO:5 mg/mL (11.56 mM);Ethanol:2 mg/mL (4.62 mM)

CC(C)(C)OC(=O)C1=CC(=C(C=C1)NC23CC4CC(C2)CC(C4)C3)N=CC5=CN=CN=C5

——

(-20℃)

With Ice Pack

≥ 2 years